Advertisement

Clinical Drug Investigation

, Volume 18, Issue 6, pp 481–483 | Cite as

Low-Dose Bezafibrate-Associated Myositis in a Patient with Chronic Renal Failure

  • I. Gotsman
  • Y. S. Haviv
  • Ran Nir-Paz
Case Report

Keywords

Adis International Limited Myositis Bezafibrate Clin Drug Invest Muscle Enzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yeshurun D, Dakak N, Khoury K, et al. Acute severe myositis due to bezafibrate treatment. Harefuah 1989; 116: 261–3PubMedGoogle Scholar
  2. 2.
    Zimetbaum P, Frishman WH, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol 1991; 31: 25–7PubMedGoogle Scholar
  3. 3.
    Yeshurun D, Abukarshin R, Elias N, et al. Long-term bezafibrate treatment in a lipid clinic. Harefuah 1992; 122: 632–4PubMedGoogle Scholar
  4. 4.
    Williams J, Baker F, Walls J. The short term effects of bezafibrate on hypertriglyceridaemia of moderate to severe uraemia. J Clin Pharmacol 1984; 18: 361–7Google Scholar
  5. 5.
    Runpf KW, Barth M, Belch M, et al. Bezafibrate induced myolysis and myoglobinuria in patients with impaired renal function. Klin Wochenschr 1984; 62: 346–8CrossRefGoogle Scholar
  6. 6.
    Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 25 Suppl. 3: 32–40PubMedGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Departments of Medicine, Hadassah University HospitalHebrew University, Hadassah Medical SchoolJerusalemIsrael
  2. 2.Department of Nephrology, Hadassah University HospitalHebrew University, Hadassah Medical SchoolJerusalemIsrael

Personalised recommendations